The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
Seiichi MawatariKohei OdaKazuaki TabuSho IjuinKotaro KumagaiKunio FujisakiMasafumi HashiguchiYukiko InadaHirofumi UtoYasunari HiramineTakeshi KureTakeshi HoriOki TaniyamaAi KasaiTsutomu TamaiAkihiro MoriuchiAkio IdoPublished in: PloS one (2018)
Although SOF/LDV therapy resulted in a high SVR12 rate, coexisting NS5A and NS5B RASs were associated with virologic failure. These results might indicate that the coexisting baseline RASs influence the therapeutic effects of SOF/LDV.